Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's Gonzo advice! Hunter S Thompson couldn't have written it better.. . Lizard people do exist and we should def not stop since this is still bat country.
Thanks for that inspired assessment and I agree on all accounts.
After contacting the PI for the Allay study in early Nov, I was told they recruitment was at 80% and eta for completion of study was May... So no applications until Q3-4 next year.
That's not a testement to great leadership... When he's nice and ready!?! What kind of a condition is that? What value is he still providing? And don't get me wrong, I respect the guy, but that doesn't mean he's making good decisions for the company at this point. And a threat of a RS does not help your case one bit.
I've been investing and waiting for 10 years not because of AW but because ofthe technology and its potential to reduce human suffering... AW didn't invent this, he's just trying to bring it to market and not very successfully at that. Maybe due to his stubbornness and inability to settle for less than perfect deals,or for failing to recognize his own drawbacks (i.e. Like public speaking - why is he involved in radio interviews when he sounds senile, or the false positives about the strength of their FDA applications)... Could this tech have wider adoption by now with someone more flexible and more willing to share the throne and limelight? Hats off to AW for getting us this far but it seems like they keep making the same mistakes from 8 years ago and the only ones paying the price are the shareholders and pain sufferers who desperately need access to this device.
Thank you for your feedback! Seems like BIEL thought that the 2017 clearance was green light from the FDA and decided to not pay the PROS to get us through the finish line... Here's to saving a buck and losing a million. I'm sure Keith hates missing this wide when a strike ball is thrown.
Can this have anything to do with the convertable shares being dumped by bond holders or Ibex knowing that know sp won't rise overnight? BIEL still needs to pay their bills somehow... Also curious about your opinion on whether FDA was not for thcoming on the clinical data being deficient vs BIEL mngmt being overly optimistic?
Well put and simply stated! But if it's that simple and straight forward why in the world did Sree and co not ask in advance and clarify if this will be an issue and how it might be addressed before getting denied after 6 months of waiting and "praying"? Or was it that we, the shareholders should have been praying according to AW?!? Do you also know if the same star studded legal team in this application just like the one the got cleared back in 2017?
Either the FDA has an agenda to prevent this tech from gaining wider acceptance or the BIEL management team was overly optimistic in their assessment of the data quality... which one is it in your opinion?
It's not about size, but effectiveness and corruption... I'd settle for a gov agency that's not in the pocket of big pharma and and actually protects consumer interests - like clearing a new effective pain mgmt device without side effect.
And again thank you for your calm and steadfast insight!
Seems hard to fathom that they can lose the approval while winning the innovation challenge, but I'm sure it's a different analysis and people involved...
It would be truly Karmic if another division in the FDA grants access to the innovation challenge, while quickly throwing mud on the face of the 510K panel that rejected the Actipatch. In this scenario the media might actually start asking pointed questions about why this technology isn't being used more extensively in the US.
Mtoronto thank you for the knowledge!
Do you know if the company is reaching out to congressmen that had previously voiced support for approving Actipatch and if BIEL is trying to organize political pressure regarding this decision?
Seems like the FDA has a lot to answer for considering they approved a new opiate 1000x stronger than morphine in a rushed and expedited session less than a month ago but can't seem to find the cajonez when approving this side-effect free device.
Wish these 2 examples were printed side by side in the media to illuminate the FDA incompetence in promoting and mismanaging the opioid epidemic.
I think you're right!!! The graphics and wording are too close to Actipatch to be just a coincidence...
I stipulated back in the summer, BIEL is probably waiting for the FDA clearance to get a giant upfront from a big player like Dr. Scholls so they can market the device for more than just feet and knees from day 1 :)
If this is for the future roll out of Actipatch we are set!
Oxford has confirmed that their trial was withdrawn by the principal investigator (Dr. Aziz)... no official reason provided but somebody on FB mentioned it was because of personnel changes.
Too bad, cause this study could have provided a stamp of approval from a world class research institution.
The mentions were made in the public comment for this meeting that closed 2 months ago... lots of patient activism.
Greater access to self-treatment through neuromodulation mentioned right before lunch break... I swear the chairwoman almost slipped and mentioned Actipatch by name :) Probably over 50 comments were left mentioning ActiPatch.
The next year for Bioelectronics should be very interesting!
Pain Management Best Practices Inter-Agency Task Force Meeting
Happening Now!
https://www.hhs.gov/live/live-1/index.html#9108
Key Recommendation Panel 1:
*Use of non-opiod medications along with non-pharmacologic treatments should be utilized as first-line therapy whenever possible in the in-patient and out-patient settings.
*Make harm-free, self-administered therapies, such as TENS, freely available to support pain management treatment plans.
You know what's more effective and better value than TENS?!?! -
ActiPatch is the obvious new game-changing modality that will also become freely available :)
The redesigned tryactipatch.com site is super sleek and feels like a multi-billion dollar pharmaceutical product page. Little by little... You know when - as some like to say.
Go team BIEL!
Mahmoud Maassarani, Ph.D is our man! He's the primary researcher running both clinical studies in Lebanon (total knee replacement).
My personal assumption - I can't imagine Dr. Maassarani would initiate a new Cesarean clinical study using RecoverRx without having confidence in the device's efficacy (maybe indicating positive results from the total knee replacement study, which was started back in Dec 2017?).
New clinical study - Pulsed Short Wave Therapy In Cesarean Section- haven't seen anyone announce or post about this... seems like a big deal if positive results are reported.
Posted on 7/27/18
250 participants
Already recruiting...
Study completion date - 12/30/18
https://clinicaltrials.gov/ct2/show/NCT03604068?term=shortwave+therapy&rank=2
The more people that ping these journalists/outlets about Actipatch, the higher the chances this story gets the attention it deserves. Not sure if writers care if a story tip came from an investor or a curious potential patient in pain....
And I did contact the company to ask for a media-outreach template but got no concrete response... seems like they're too busy these days to spend time on small-fry requests like this :)
If you want to be helpful, please contact the media (I have).
Here's a couple of lists of top healthcare journalists in the nation:
https://healthjournalism.org/awards-winners.php?Year=2016
https://blog.bernardhealth.com/bid/201988/10-healthcare-journalists-you-should-be-following-on-Twitter
Please spend a few minutes and tweet or email anyone on these lists and ask them to opine on https://globenewswire.com/news-release/2018/01/04/1283220/0/en/BioElectronics-ActiPatch-Drug-Free-Pain-Therapy-Receives-United-Kingdom-National-Health-System-Payment-Coverage.html
Aren't the NHS findings newsworthy? Doesn't this this technology deserve additional media attention based on its efficacy?!?
Instead of debating here with day traders you could write a quick note to NYTimes or BBC Health and provide the impetus for Actipatch to show up on the front page.
I agree that the convertible debt is the biggest risk to the upside being >10x, now that the FDA seems to be finally capitulating.
Having Andy go on record about their exact plan for retiring CD would be incredibly beneficial.
Oxford clinical investigator bio quote:
"I am also conducting a clinical trial into inexpensive pain relief treatments that, if shown to be effective, could substantially improve the treatment of pain worldwide."
https://www.nds.ox.ac.uk/team/laurie-pycroft
https://clinicaltrials.gov/ct2/show/NCT02601807?term=actipatch&rank=1
Trial should be completed soon (around May 2018) and if we get positive news from Oxford how do you think the SP will react?
Give the Dr and his production team some credit... if he's legit, once he sees the data it should be a no brainer.
Additional "public" goading is probably not needed (and might seem somewhat suspicious) because you already lit the match!
Well done!
I've previously sent product activist letters to NPRs Biotech Nation (they directly interacted as a result) and Gizmodo Health, with not much luck up to this point.
I'm thinking we might want to create a "product activist" template for media outreach (radio, newspaper, local tv stations) that focuses only the technology and its benefits, rather than BIEL investors.
This way we can all quickly and easily copy and paste the plea for additional media coverage and distribute to our local medial channels...
This is what I sent to Gizmodo (maybe a 1st draft but I'm no Mark Twain), but we'd def need to make it more generic:
Your article about synthetic opioid deaths in the US is incredibly pertinent and relevant considering the number of annual deaths and millions of lives and families negatively impacted that aren't even collected in these statistics... (https://gizmodo.com/deaths-from-synthetic-opioids-doubled-from-2015-to-2016-1824191467)
It made me wonder if you ever heard of a new wearable medical technology that recently cleared the FDA and NHS to reduce chronic pain: The Actipatch? The primary indication is for chronic and localized pain. No drugs, no major side-effects… Just a little magic loop that takes pain away: http://www.actipatch.com/why-actipatch/how-actipatch-works/
This tech is proven to help people reduce their need for opioids, potentially saving families from going through the trauma of narcotic addiction and saving countless lives...
What’s more, the “NHS found that ActiPatch significantly decreased pain and improved quality of life, while reducing overall healthcare costs by 42% (58.5% reduction in physician appointment costs, 35% reduction in prescription medication costs)” - https://globenewswire.com/news-release/2018/01/04/1283220/0/en/BioElectronics-ActiPatch-Drug-Free-Pain-Therapy-Receives-United-Kingdom-National-Health-System-Payment-Coverage.html - and the tech is now covered by the NHS for all UK citizens.
I think this Star Trek like technology and gizmo is worthy and deserving of some publicity to provide pain sufferers a drug-free medically proven alternative that's cool as hell??
Cheers and thank you for shinning a light on new technology and information that helps inform your readers of developments in health sciences.
Thinking BIEL is waiting until full body clearance before completing the Dr Scholls deal.
If they're able to market that it will help treat all Musculoskeletal Pain in the foot rather than just Plantar fasciitis, Andy and Co can demand multiples more in value from the licensing deal... think about it.
As for me, 9 years later, what's another 4 months to wait for the real fireworks to start?!?
And up or down always remember, we're the good guys fighting the good fight here... This technology and company reduces pain and suffering and if successful, in the long run, will save the global healthcare system 100s of billions of dollars and countless lives from reducing the reliance on narcotics.
Be proud of this investment and good luck to everyone!
The BIELionaire club is recruiting new members that can see the writing on the wall.
Oxford back pain study response... Around this time last year I emailed one of the contacts for the study about updating the info on the clinicaltrials.gov and the completion timeline. This is the response that I got:
"It should be updating to the new date soon - probably May 2018. Have been some recruitment delays, but it's still ongoing and we're recruiting more participants.
Best wishes,"
Unfortunately, they never updated the website but the response could be interpreted as an expansion of the trial size (and could explain the long delay from the originally planned trial end date of Oct 2016).
Could be big and announced any day now...
Especially when compared to the last 5 years of SP performance...
BIEL never rose gradually in the past, but rather spiked and dropped on news and speculation. This time we've risen 200% over 4 months which is a sure sign that things are very different for BIEL these days...
One word - profitable!
From Keith's LinkedIn account:
Our session at the Australian Pain Society was one of 2 that was fully registered. People all over the world are seeking options for pain treatment, Actipatch carries sound clinical evidence, 5 active clinical trials and a talented team of "Phds" to match any big pharma company.
Boots.com went from "Out of stock" for Actipatch, to not listing them at all online... Clear indication to me that BIEL is close to launching the consolidated SKU so they can place the 7 day Trial on store shelves. Thoughts?
Response from Weldricks for online NHS orders:
"If you have a NHS prescription for Actipatch, please place your order via the website, please opt for NHS prescription (no description of goods necessary), if you pay for your prescriptions you will be prompted to make the £8.80 charge, if exempt please tick to back of the prescription.
If you have a private prescription, please let me know as I can add the products to our prescription section for you."
... And I'd wager it's just as easy to do from the Boots website.
I already accounted for that by reducing the Weldricks per hour sales from 24 to 10.
Corrections - Sales forecast starting Q2
I forgot to multiply the sales by 24 hours which would mean Weldricks would sell 240 units sold online per day... that means all my estimates would have to be multiplied by 24 which I don't think is realistic (3.6M per quarter?!?), so maybe the volumes they display are for both internet and in-store?
If that's the case, my math should have multiplied the unit forecast by 24 (hours) and then divide by 5 (if in-store sales are included) - getting to a 720,000 per quarter starting Q2?!?
This still seems really high - anyone see any other glaring mistakes in my math?
Great find! It is probably most effective to email these guys direclty instead of the generic NCCIH Press Office:
Steven George, Ph.D., Duke University, Durham, North Carolina. The goal of this planning and demonstration project is to improve access to recommended nondrug therapies for low-back pain in the Department of VA Health Care System. (Funded by NCCIH)
Marc Rosen, M.D., Yale University, New Haven, Connecticut. This research will test the effectiveness and cost-effectiveness of Screening, Brief Intervention, and Referral to Treatment for Pain Management, designed to reduce pain and risky substance use. (Funded by NCCIH, NIDA)
Extrapolating from the Weldricks sales info...
Weldricks - 64 pharmacies
Let's assume on average they are selling 10 Actipatchs online per hour every day, representing 20% of total sales, which comes out to 50 Actipatches an hour online/in store sales. 50 * 30 days = 1500 units a month...
Now Boots - 2500 pharmacies - 39 times the size of Weldricks. Let's assume they only 50% as effective as Weldricks in selling... that's still 20 x 1500 = 30,000 units per month - Is that the reason why their online store is out of stock?!? - http://www.boots.com/search/actipatch#facet:-10026599116105809711699104&productBeginIndex:0&orderBy:&pageView:&minPrice:&maxPrice:&pageSize:&;
Now Lloyds - 1,500 pharmacies - 23 times the size of Weldricks. Using the same math as Boots, that's 11 x 1500 = 16,500 units per month.
So for just Weldricks, Boots, and Lloyd in the UK, I'm getting 144,000 units sold per quarter.
That's estimated sales without:
*The Braum hip/knee surgery program in the UK (not including Germany) - 120,000 per quarter
*Mass advertising NHS coverage
*Allay sales - ???
*The US back clearance - ?!?
*US Performance Health channel - ??? per quarter
*MundiParma channel - ???
*Licensing agreements for Heal Pain - ???
*Licensing agreements for Actipactch - ???
I'm estimating BIEL is now selling at least 150,000 units in Q1 based on all the available information... Please let me know if you think my math is off somewhere!
Also noticed that if you scroll down on the Waldricks Parmacy portal (https://www.weldricks.co.uk/) and scroll to the right in the bestsellers section you'll find Actipatch :) And they also list the volume for (assuming for online) sales - "2 sold in the last hour" https://www.weldricks.co.uk/products/actipatch-muscle-joint-pain-relief-1
Gordon's Pharmacy lists Actipatch as a popular Health brand (https://www.gordonsdirect.com/healthcare.html)...
And all of this traction before any promotion in the UK that Actipatch is covered by NHS.
Tsunami incoming!
Love how Boots online is out of stock, even though all the stores seem to be stocked no matter what postal code I check... http://www.boots.com/search/actipatch
Also the Joint Pain Relief version (with just the loop) seems to have disappeared as an option. Is this an indication they are close to consolidating the SKUs and launching the new packaging mentioned in the shareholder update?
My guess is that once BIEL becomes profitable via sales and/or licensing agreements they would have to payoff these convertible notes to secure larger institutional investors. Which will happen as long as the Whalens are guaranteed a big payout... and I'm ok with that because in that scenario we ALL win :)
Thanks for the reply.
Doesn't this boil down to IBEX having +50% share control via convertible notes, and in reality all current shareholders comprise less than half of the potential share count if the entire conversion takes place.
What's to prevent IBEX converting and selling ALL their shares over the next 10 years as the SP increases?
With larger investors knowing that 50% of the shares are still on sideline owned by IBEX, their $1000 investment immediately turns into $500 if IBEX decides to convert their notes... or am I missing something?
Could someone please provide context around NOTE 7 – RELATED PARTY NOTES PAYABLE section which states "the corresponding shares to be issued on the conversion of these IBEX notes has
increased to 19,658,867,082 at December 31, 2017."
Does this mean IBEX can convert their loan to into 19.65 Billion shares on Dec 31?
I know IBEX is owned by Kelly Whelan so she presumably doesn't want to dilute the SP of BIEL considering it's all in the family... In that case, is the plan for BIEL to just pay off the note (once profitable) instead of IBEX converting the debt into shares?
If I'm speculating correctly, does anyone think they're using this financing strategy to prevent ia hostile takeover by interested parties buying up 50.1% of the shares? If someone did, IBEX could just follow up on the debt conversion, maintaining 50.1% between the Whelan clan... Any thoughts?